Oncoloxía médica
Servicio
Seoul National University Hospital
Seúl, Corea del SurPublicacións en colaboración con investigadores/as de Seoul National University Hospital (5)
2023
-
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
Expert Review of Anticancer Therapy, Vol. 23, Núm. 1, pp. 95-106
2021
2020
-
Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial
Journal of Clinical Oncology
-
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
The Lancet Respiratory Medicine, Vol. 8, Núm. 11, pp. 1132-1143
2018
-
Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer
New England Journal of Medicine, Vol. 379, Núm. 21, pp. 2027-2039